Comparison of Prolactin, CA 15–3 and TPA in Breast Carcinomas

Jm, Bhatavdekar; Sn, Trivedi; Shah, Neelam G.; Patel, Dev; Nh, Karelia; Shukla, MK; Ghosh, Nandita; Hh, Vora

doi:10.1177/172460088900400304

Cited by 8 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4][5][6][7][8][9][10][11] This was further evaluated in male patients with colorectal cancer. Our results point toward the significant role of serum PRL as prognosticator and disease monitor in patients with breast cancer.…”

Section: Accepted 7 July 1999mentioning

confidence: 99%

Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience

Patel

Vora

et al. 2000

Head Neck

View full text Add to dashboard Cite

Background The purpose of this study was to assess the role of prolactin (PRL) in men with locally advanced tongue cancer. Methods Circulating PRL was assayed immunoradiometrically in pretherapeutic and sequential blood samples of 99 patients with locally advanced tongue cancer. Patients were followed for 3 years or until their death within a stipulated time. Immunohistochemical localization of PRL was performed on formalin‐fixed paraffin‐embedded tissue sections. Tumoral prolactin receptors (PRLR) were estimated by ligand binding assay; the expression of PRL mRNA and PRLR mRNA were carried out by reverse transcriptase polymerase chain reaction (RT‐PCR). Furthermore, PRL amplimer was sequenced and compared with human pituitary PRL amplimer. Results Pretherapeutic PRL levels were significantly higher in patients with locally advanced tongue cancer compared with controls (p = .01). Thirty‐four percent (34 of 99) of the patients had hyperprolactinemia (PRL ≥15.0 ng/mL). Univariate survival analysis showed that patients with pretherapeutic hyperprolactinemia had a significantly shorter overall survival than patients with pretherapeutic PRL <15.0 ng/mL serum (p = .0009). In multivariate analysis, PRL emerged as the most significant independent prognostic factor influencing overall survival. Furthermore, changes in serial PRL levels showed excellent correlation with response to therapy and progression of disease. Forty‐four percent (24 of 54) of the tumors showed positive immunoreactivity with PRL antibody, indicating that PRL or a molecule similar to it is produced by tongue tumors. PRL mRNA expression was seen in 85% (43 of 50) of the tumors and confirmed the de novo synthesis of PRL. Sequence analysis of the 234 bp PRL amplimer revealed that the sequence was homologous to exon 5 of pituitary PRL mRNA. The action of PRL is mediated by PRLR, and it was observed that the PRLR positivity by ligand binding assay was 33%. The expression of PRLR mRNA by RT‐PCR showed two forms of PRLR mRNA (ie, intermediate form [500–600 bp] seen in 82% (41 of 50 ) of the tumors and the long form [800–900 bp] seen in 36% (18 of 50) of the tumors. In 82% (41 of 50) of the tumors, either the intermediate or long form was seen. Conclusions This multifaceted study of PRL suggests that tongue cancer cells produce PRL, and this ectopically produced PRL might be acting as a major local growth promoter by means of autocrine and paracrine mechanisms. Looking at its prognostic value and correlation with disease activity, it may provide new insights into treatment of tongue cancer. © 2000 John Wiley & Sons, Inc. Head Neck 22: 257–264, 2000.

show abstract

Section: Accepted 7 July 1999mentioning

confidence: 99%

Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience

Patel

Vora

et al. 2000

Head Neck

View full text Add to dashboard Cite

show abstract

“…Our results point toward the significant role of serum PRL as prognosticator and disease monitor in patients with breast cancer. [1][2][3][4][5][6][7][8][9][10][11] This was further evaluated in male patients with colorectal cancer. Surprisingly, we found similar results.…”

Section: Abstract: Locally Advanced Tongue Cancer; Prolactinmentioning

confidence: 99%

Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience

Jm¹,

Patel²,

Vora³

et al. 2000

Head Neck

View full text Add to dashboard Cite

Abstract:Background. The purpose of this study was to assess the role of prolactin (PRL) in men with locally advanced tongue cancer.Methods. Circulating PRL was assayed immunoradiometrically in pretherapeutic and sequential blood samples of 99 patients with locally advanced tongue cancer. Patients were followed for 3 years or until their death within a stipulated time. Immunohistochemical localization of PRL was performed on formalin-fixed paraffin-embedded tissue sections. Tumoral prolactin receptors (PRLR) were estimated by ligand binding assay; the expression of PRL mRNA and PRLR mRNA were carried out by reverse transcriptase polymerase chain reaction (RT-PCR). Furthermore, PRL amplimer was sequenced and compared with human pituitary PRL amplimer.Results. Pretherapeutic PRL levels were significantly higher in patients with locally advanced tongue cancer compared with controls (p = .01). Thirty-four percent (34 of 99) of the patients had hyperprolactinemia (PRL Ն15.0 ng/mL). Univariate survival analysis showed that patients with pretherapeutic hyperprolactinemia had a significantly shorter overall survival than patients with pretherapeutic PRL <15.0 ng/mL serum (p = .0009). In multivariate analysis, PRL emerged as the most significant independent prognostic factor influencing overall survival. Furthermore, changes in serial PRL levels showed excellent correlation with response to therapy and progression of disease. Forty-four percent (24 of 54) of the tumors showed positive immunoreactivity with PRL antibody, indicating that PRL or a molecule similar to it is produced by tongue tumors. PRL mRNA expression was seen in 85% (43 of 50) of Conclusions. This multifaceted study of PRL suggests that tongue cancer cells produce PRL, and this ectopically produced PRL might be acting as a major local growth promoter by means of autocrine and paracrine mechanisms. Looking at its prognostic value and correlation with disease activity, it may provide new

show abstract

Tumor markers in patients with advanced breast cancer as prognosticators: A preliminary study

Patel

et al. 1994

Breast Cancer Res Tr

View full text Add to dashboard Cite

A retrospective study was performed on 69 breast cancer patients (stage II, N = 18; advanced disease, N = 51) in order to assess the prognostic value of circulating prolactin (PRL), CEA, CA 15-3, insulin-like growth factor-1 (IGF-1), and epidermal growth factor (EGF) by RIA/IRMA. These markers were compared with short-term prognosis (two years). Significant difference was observed only for PRL ( < 20.0 ng/ml vs. > 20.0 ng/ml), which provide an independent predictor of short-term prognosis in advanced breast cancer.

show abstract

Comparison of Prolactin, CA 15–3 and TPA in Breast Carcinomas

Cited by 8 publications

References 6 publications

Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience

Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience

Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience

Tumor markers in patients with advanced breast cancer as prognosticators: A preliminary study

Contact Info

Product

Resources

About